Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neoplasm Metastasis 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × dactolisib × Clear all
NCT02430363 2016-02-24

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Medical Research Council

Phase 1/2 Unknown
58 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡